Literature DB >> 19188386

Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.

Peter J Petersen1, C Hal Jones, Aranapakam M Venkatesan, Patricia A Bradford.   

Abstract

The in vivo efficacy of piperacillin in combination with the penem inhibitor BLI-489 was determined using acute lethal systemic infections in mice. On the basis of preliminary results with various ratios, a dosing ratio of 8:1 was found to be optimal for retention of enhanced efficacy. Piperacillin-BLI-489 dosed at an 8:1 ratio was efficacious against murine infections caused by class A (including extended-spectrum beta-lactamases), class C (AmpC), and class D beta-lactamase-expressing pathogens.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19188386      PMCID： PMC2663108          DOI： 10.1128/AAC.01549-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.

Authors:  L A Miller; K Ratnam; D J Payne
Journal:  Curr Opin Pharmacol       Date:  2001-10       Impact factor: 5.547

Review 2.  Plasmid-borne AmpC beta-lactamases.

Authors:  Jan Walther-Rasmussen; Niels Høiby
Journal:  Can J Microbiol       Date:  2002-06       Impact factor: 2.419

Review 3.  The impact of beta-lactamases on the development of novel antimicrobial agents.

Authors:  Karen Bush
Journal:  Curr Opin Investig Drugs       Date:  2002-09

Review 4.  Beta-lactamase inhibitors: agents to overcome bacterial resistance.

Authors:  S N Maiti; O A Phillips; R G Micetich; D M Livermore
Journal:  Curr Med Chem       Date:  1998-12       Impact factor: 4.530

Review 5.  Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms.

Authors:  M Gniadkowski
Journal:  Clin Microbiol Infect       Date:  2001-11       Impact factor: 8.067

6.  Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.

Authors:  Aranapakam M Venkatesan; Atul Agarwal; Takao Abe; Hideki Ushirogochi; Itsuki Yamamura; Toshio Kumagai; Peter J Petersen; William J Weiss; Eileen Lenoy; Youjun Yang; David M Shlaes; John L Ryan; Tarek S Mansour
Journal:  Bioorg Med Chem       Date:  2004-11-15       Impact factor: 3.641

7.  Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.

Authors:  G Barnaud; R Labia; L Raskine; M J Sanson-Le Pors; A Philippon; G Arlet
Journal:  FEMS Microbiol Lett       Date:  2001-02-20       Impact factor: 2.742

Review 8.  Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.

Authors:  J C Pechère; W Wilson; H Neu
Journal:  J Antimicrob Chemother       Date:  1995-11       Impact factor: 5.790

Review 9.  Novel beta-lactam antibiotics and inhibitor combinations.

Authors:  Matteo Bassetti; Elda Righi; Claudio Viscoli
Journal:  Expert Opin Investig Drugs       Date:  2008-03       Impact factor: 6.206

10.  Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate.

Authors:  G Barnaud; Y Benzerara; J Gravisse; L Raskine; M J Sanson-Le Pors; R Labia; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
View more
  7 in total

Review 1.  Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.

Authors:  Carine Bebrone; Patricia Lassaux; Lionel Vercheval; Jean-Sébastien Sohier; Adrien Jehaes; Eric Sauvage; Moreno Galleni
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

Review 2.  Class D β-lactamases: a reappraisal after five decades.

Authors:  David A Leonard; Robert A Bonomo; Rachel A Powers
Journal:  Acc Chem Res       Date:  2013-07-31       Impact factor: 22.384

Review 3.  Overcoming resistance to β-lactam antibiotics.

Authors:  Roberta J Worthington; Christian Melander
Journal:  J Org Chem       Date:  2013-03-28       Impact factor: 4.354

Review 4.  Combination approaches to combat multidrug-resistant bacteria.

Authors:  Roberta J Worthington; Christian Melander
Journal:  Trends Biotechnol       Date:  2013-01-18       Impact factor: 19.536

5.  Phenotypic prevalence of extended spectrum beta-lactamases among enterobacteriaceae isolated at Mulago National Referral Hospital: Uganda.

Authors:  Lucas Ampaire; Emmanuel Nduhura; Izale Wewedru
Journal:  BMC Res Notes       Date:  2017-09-06

6.  Cyclic Boronates Inhibit All Classes of β-Lactamases.

Authors:  Samuel T Cahill; Ricky Cain; David Y Wang; Christopher T Lohans; David W Wareham; Henry P Oswin; Jabril Mohammed; James Spencer; Colin W G Fishwick; Michael A McDonough; Christopher J Schofield; Jürgen Brem
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.

Authors:  Jun-Ichi Wachino; Wanchun Jin; Kouji Kimura; Hiromasa Kurosaki; Ayato Sato; Yoshichika Arakawa
Journal:  mBio       Date:  2020-03-17       Impact factor: 7.867
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.